Personalized Binuclear Enzyme Inhibition Platform

Publication ID: 24-11857657_0010_PTD

Published: October 28, 2025

Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Personalized Binuclear Enzyme Inhibition Platform,” Published Technical Disclosure No. 24-11857657_0010_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857657_0010_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,657.

Summary of the Inventive Concept

A next-generation platform for treating diseases and conditions mediated by binuclear enzymes, leveraging AI-driven molecular design, personalized skin analysis, and transdermal delivery to provide customized and effective treatments.

Background and Problem Solved

The original patent disclosed diarylalkane compounds as potent inhibitors of binuclear enzymes, but it had limitations in terms of compound synthesis, skin penetration, and personalized treatment. The new inventive concept addresses these limitations by introducing AI-driven molecular design, personalized skin analysis, and transdermal delivery, enabling more effective and targeted treatments.

Detailed Description of the Inventive Concept

The platform comprises a database of diarylalkane compounds, a skin analysis module, and a recommendation engine that selects a customized diarylalkane composition based on an individual's skin type, condition, and desired outcome. The AI-driven molecular design system predicts optimal molecular structures for inhibiting binuclear enzymes and generates novel compounds for further testing and development. The transdermal delivery system ensures sustained and targeted delivery of the active ingredient. The novel class of diarylalkane compounds having modified general structures enhances bioavailability, stability, or skin penetration.

Novelty and Inventive Step

The new claims introduce AI-driven molecular design, personalized skin analysis, and transdermal delivery, which are not present in the original patent. The combination of these elements provides a novel and non-obvious solution for treating diseases and conditions mediated by binuclear enzymes.

Alternative Embodiments and Variations

Alternative embodiments may include the use of other AI algorithms, different transdermal delivery systems, or additional skin analysis parameters. Variations may include the application of this platform to other diseases and conditions beyond skin pigmentation, such as cancer or neurodegenerative diseases.

Potential Commercial Applications and Market

The personalized binuclear enzyme inhibition platform has significant commercial potential in the cosmetics and pharmaceutical industries, particularly in the areas of skin care and dermatology. The platform's ability to provide customized and effective treatments could disrupt the existing market and create new opportunities for companies and researchers.

CPC Classifications

Section	Class	Group
A	A61	A61K8/347
A	A61	A61K8/31
A	A61	A61K8/4973
A	A61	A61K8/9789
A	A61	A61K8/9794
A	A61	A61K31/015
A	A61	A61K31/05
A	A61	A61K31/085
A	A61	A61K31/09
A	A61	A61K31/357
A	A61	A61K31/40
A	A61	A61K31/704
A	A61	A61Q19/02
C	C07	C07C39/15
C	C07	C07C39/367
C	C07	C07C41/26
C	C07	C07C41/32
C	C07	C07C43/23
C	C07	C07C45/673
C	C07	C07C49/835
C	C07	C07C215/74
C	C07	C07D321/12
A	A61	A61K2800/782
Y	Y02	Y02A50/30

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Pharmaceutical and cosmetic chemistry, specifically focused on enzyme inhibition, skin treatment, and molecular design for dermatological applications involving binuclear enzyme modulation

Person of Ordinary Skill (PHOSITA) Profile

A skilled practitioner with advanced degrees in chemistry, biochemistry, or pharmaceutical sciences, experienced in molecular design, enzyme inhibition techniques, and AI-assisted drug development, with knowledge of transdermal delivery systems and personalized medicine approaches

Obviousness Rationale

A person of ordinary skill would recognize that the PTD represents a predictable extension of the source patent's core technology, applying standard AI and personalization techniques to the existing diarylalkane compound framework. The molecular design and delivery system improvements are logical progressions using known techniques in pharmaceutical development. The variations represent incremental innovations that would be obvious to a skilled practitioner seeking to optimize the original enzyme inhibition method.

Obvious Combinations & Variations

Source Patent Element

Diarylalkane compounds for treating skin pigmentation and inflammatory conditions

PTD Variation

AI-driven molecular design system for generating novel diarylalkane compound structures

Obviousness Reasoning

Predictable application of machine learning to molecular design, a known technique in pharmaceutical research for optimizing compound properties

Source Patent Element

Method of treating skin conditions by inhibiting binuclear enzymes

PTD Variation

Personalized skin analysis module for tailoring diarylalkane compound selection

Obviousness Reasoning

Obvious extension of precision medicine approaches, using individual patient characteristics to customize treatment

Source Patent Element

Topical application of diarylalkane compounds

PTD Variation

Transdermal delivery system with controlled release mechanism

Obviousness Reasoning

Known pharmaceutical engineering technique for improving drug delivery, representing a standard optimization approach

Source Patent Element

Basic diarylalkane molecular structure for enzyme inhibition

PTD Variation

Modified molecular structures with enhanced bioavailability and penetration

Obviousness Reasoning

Routine chemical modification using known structure-activity relationship principles in pharmaceutical development

Source Patent Element

Treatment of skin pigmentation and inflammatory conditions

PTD Variation

Expanded application to other diseases mediated by binuclear enzymes

Obviousness Reasoning

Predictable scientific exploration of compound's potential applications using standard research methodologies

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857657 and the published technical disclosure, a person of ordinary skill in the art would find the claimed innovations obvious, as they represent predictable variations and standard technological progressions in the field of enzyme inhibition and personalized molecular design. The combination of known techniques, including AI-driven molecular optimization, personalized treatment selection, and advanced delivery systems, would be obvious to a skilled practitioner seeking to improve upon existing diarylalkane compound technologies.

Original Patent Information

Patent Number	US 11,857,657
Title	Diarylalkanes as potent inhibitors of binuclear enzymes
Assignee(s)	Unigen, Inc.